Clinical trials: Degenerative Conditions, Neurologic
Alzheimer´s Disease
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
The purpose of this study is to evaluate whether treatment with single and multiple oral doses of AZD1446 for 1 week will have effect on Quantified Electroencephalography and Event-Related Potentials in patients with Alzheimers…
- Trial name
- NCT01125683
- Testing
- AZD1446, Donepezil
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Amyotrophic Lateral Sclerosis
Safety Extension Study of TRO19622 in ALS
The purpose of the assay is to assess the safety of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, after completion of the preceding clinical trial (TRO19622 CL E Q…
- Trial name
- NCT01285583
- Testing
- TRO19622
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 271 people
- Sponsor
- Hoffmann-La Roche
Spinal Muscular Atrophy (SMA)
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
The goal of this multicenter, open-label, non-comparative, cohort study is to investigate the safety, immunogenicity, and efficacy of ANB-004 in children with spinal muscular atrophy.
- Trial name
- BLUEBELL (NCT05747261)
- Testing
- ANB-004, dose 1, ANB-004, dose 2, ANB-004, dose 3
- Where
- 7 sites in Belarus, Russia
- Volunteers
- 40 people
- Sponsor
- Biocad
Parkinson Disease
Evaluation of Clinical Progression in Patients With Motor Predominant Parkinson Disease.
The objective of this study is the longitudinal prospective clinical evaluation in patients with motor predominant PD; it will assess the individual disease progression (change) of the clinical and imaging parameters measured at…
- Trial name
- PARK001 (NCT03960242)
- Where
- 2 sites in France
- Volunteers
- 3 people
- Sponsor
- BrainEver
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.
Healthy
A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK, study of the way a drug enters and leaves the blood and tissues over time) of single-ascending oral doses of JNJ-54861911 in healthy…
- Trial name
- NCT02180269
- Testing
- JNJ-54861911 (25 mg), JNJ-54861911 (50 mg), JNJ-54861911 (100 mg)
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Parkinson Disease, Parkinson's Disease
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
Ropinirole Hydrochloride (ROP) was granted approval for the treatment of Parkinson's Disease (PD) on 20 October 2006. ROP is expected to be used for a long term in clinical practice.
- Trial name
- NCT00485069
- Testing
- ROP, ROP+L-Dopa
- Where
- 22 sites in Japan
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease
The goal of this Phase 2 clinical trial is to learn if repeated dosing of RB-ADSC (an investigational autologous cell product obtained from participant's own adipose tissue) enhances the positive preliminary results seen in Phase…
- Trial name
- NCT07205601
- Testing
- RB-ADSC
- Volunteers
- 115 people
- Sponsor
- Regeneration Biomedical, Inc.
Alzheimer's Disease, Central Nervous System Diseases
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, and pharmacokinetics (PK) of three different doses of an investigational medication, EVP-6124, in individuals with mild to moderate Alzheimer's disease who are…
- Trial name
- NCT00766363
- Testing
- EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer´s Disease
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations in patients with Alzheimer's disease.
- Trial name
- NCT02008513
- Testing
- AFFITOPE® AD02
- Where
- 27 sites in Austria, Croatia and 4 more
- Volunteers
- 194 people
- Sponsor
- Affiris AG
Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
The main purpose of the study was to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with AD.
- Trial name
- NCT04339413
- Testing
- Gantenerumab
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Degenerative
3VM for Treatment of Chronic Osteoarthritis Knee Pain
A double-blind, placebo-controlled, randomized dose ranging study for the use of 3VM1001 Cream, 2g three times daily, 3g three times daily, or 3g four times daily for treatment of chronic pain associated with osteoarthritis of…
- Trial name
- NCT03142178
- Testing
- Experimental: 3VM1001 active 2g Cream 3 times daily, Experimental: 3VM1001 active 3g Cream 3 times daily, Experimental: 3VM1001 active 3g Cream 4 times daily
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- CDA Research Group, Inc.
Parkinson's Disease
Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.
The purpose of this study was to evaluate the differences in safety and efficacy between Parkinson's disease patients who either received transplantation of fetal porcine cells or placebo treatment.
- Trial name
- NCT00226460
- Testing
- Fetal porcine cells, Neurocell-PD
- Where
- United States
- Sponsor
- Genzyme, a Sanofi Company
Parkinson's Disease
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria…
- Trial name
- Safinamide-LID (NCT01113320)
- Testing
- Safinamide
- Where
- 11 sites in Austria, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Newron Pharmaceuticals SPA
Alzheimer Disease
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
- Trial name
- NCT03901092
- Testing
- flortaucipir F 18
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Avid Radiopharmaceuticals
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT04658199
- Testing
- UCB0107 (bepranemab)
- Where
- 11 sites in Belgium, Germany and 2 more
- Volunteers
- 19 people
- Sponsor
- UCB Biopharma SRL
Parkinson's Disease, Movement Disorder Syndrome
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.
- Trial name
- NCT00199433
- Testing
- Istradefylline (KW-6002)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Kyowa Kirin, Inc.
Alzheimer's Disease
Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163
The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.
- Trial name
- NCT01454115
- Testing
- BMS-708163 (Gamma-Secretase Inhibitor)
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with…
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05176717
- Testing
- QR-421a
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Laboratoires Thea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.